Alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as RNA interference, or RNAi.

Angiochem is creating a new class of pharmaceuticals that achieve meaningful outcomes in a wide range of CNS diseases, including brain cancer, neurodegenerative and metabolic diseases, pain, and many others.

Avila Therapeutics designs and develops targeted covalent drugs that precisely inhibit targets to achieve best-in-class outcomes that cannot be achieved through traditional medicinal chemistry.

BIND Therapeutics is developing a new class of highly selective targeted therapeutics called Accurins™ that selectively accumulate at the site of disease, dramatically enhancing efficacy while minimizing effects on healthy tissues.

Blend Therapeutics is discovering and developing integrative combination medicines with the unprecedented ability to precisely control each agent’s therapeutic action in concert.

Concert Pharmaceuticals uses deuterium-based chemistry to create and develop highly differentiated new medicines by leveraging decades of pharmaceutical and clinical experience to reduce time, risk, and expense.

Eleven Biotherapeutics creates first-of-a-kind protein-based drugs with significantly improved physical, pharmaceutical, and therapeutic benefits.

Ensemble Therapeutics is developing a novel class of therapeutics, called Ensemblins™, that open up new ways to treat diseases by addressing drug targets that are currently inaccessible with conventional small-molecule drugs.

ImmunoGen develops targeted anticancer therapeutics using expertise in cancer biology, engineered antibodies, and highly potent cancer cell-killing agents.

Kala Pharmaceuticals is developing innovative medicines that have the unprecedented ability to rapidly and effectively penetrate mucosal barriers resulting in superior therapeutic efficacy and transformative treatment outcomes for patients.

Knome specializes in the interpretation of human whole genomes and provides academic, pharmaceutical, and biotech researchers services and software to investigate the genetic basis of disease and drug response.

MicroCHIPS is pioneering intelligent implanted devices designed to improve the health of millions of people with chronic conditions that require careful monitoring and precise therapy.

N-of-One is powering personalized medicine for oncology through PrecisionWorks™, a knowledge integration platform for individualized cancer care. PrecisionWorks enables N-of-One to deliver integrated report products and procedural support services that help target what is most relevant and effective for each individual patient—each “n of one.”

Promedior is developing a novel biology platform for the treatment of fibrosis, inflammation, and neovascular retinal diseases.

Pulmatrix is discovering and developing a new class of inhaled therapies for the prevention, treatment, and control of respiratory diseases.

RaNA Therapeutics is using its proprietary RNA upregulation platform to discover and develop highly selective epigenetic modulators of gene expression.

Selecta Biosciences is developing a new class of targeted vaccines that induce an antigen-specific immune activation or an antigen-specific immune tolerance for therapeutic and prophylactic application.

TremRx has a proprietary technology platform to create and administer highly effective vaccines that are delivered to the upper layers of skin, rather than to deeper layers of skin or muscle as conventional vaccines are delivered.